Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

According to Benzinga Pro, Intellia Therapeutics's peer group average for short interest as a percentage of float is 14.00%, which means the company has more short interest than most of its peers. Did ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.